This pattern remains the same on day 5 of assessment, where there is a significant 23-fold reduction in CASP3 level (p < 0.001) and a 2-fold increase in GST level (p = 0.043) in the rNT3 treatment group compared to the corresponding PD group. This evidence concerns the gene CASP3 and Parkinson disease.